Control of melanoma invasiveness by anticollagenolytic agents: A reappraisal of an old concept

Anti-Cancer Agents in Medicinal Chemistry

Volumn 9, Issue 5, 2009, Pages 576-597

  Bourguet, Erika ^a   Sapi, Janos ^a   Emonard, Hervé ^a   Hornebeck, William ^a  

^a UNIVERSITÉ DE REIMS CHAMPAGNE ARDENNE   (France)

Author keywords

Collagen; Collagenase; Exosite; Inhibitors; Matrix metalloproteinases; Melanoma

Indexed keywords

4 [[[4 (4 CHLOROPHENOXY)PHENYL]SULFONYL]METHYL]TETRAHYDRO 2H PYRAN 4 CARBOHYDROXAMIC ACID; ABT 518; ANTICOLLAGENOLYTIC AGENT; BATIMASTAT; BENZODIAZEPINE; CGS 27023A; CIPEMASTAT; CL 82198; COLLAGENASE; COLLAGENASE 3; COLLAGENASE 3 INHIBITOR; COLLALGENASE 1 INHIBITOR; CYCLOFENIL; D 1927; GELATINASE A; GELATINASE A INHIBITOR; ILOMASTAT; INTERSTITIAL COLLAGENASE; MARIMASTAT; MATRIX METALLOPROTEINASE 14 INHIBITOR; MATRIX METALLOPROTEINASE INHIBITOR; MMI 270; NEUTROPHIL COLLAGENASE; PRINOMASTAT; PYRIMIDINEDIONE; REBIMASTAT; S 3304; SOLIMASTAT; TANOMASTAT; UNCLASSIFIED DRUG; UNINDEXED DRUG; WAY 170523;

AMINO TERMINAL SEQUENCE; ARTHRITIS; ARTICLE; CANCER CONTROL; CANCER GROWTH; CANCER INCIDENCE; CANCER INVASION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; COLLAGEN DEGRADATION; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG MECHANISM; DRUG STRUCTURE; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME BINDING; ENZYME STRUCTURE; EYE DISEASE; HUMAN; IC 50; INFLAMMATION; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; NONHUMAN; OSTEOARTHRITIS; PROTEIN PROCESSING; RETINA MACULA DEGENERATION; RHEUMATOID ARTHRITIS; TREATMENT INDICATION;

EID: 67651112138     PISSN: 18715206     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152009788451842     Document Type: Article

References (178)

1. Thompson, J.F.; Scolyer, R.A.; Kefford, R.F. Cutaneous melanoma. Lancet, 2005, 365(9460), 687-701.
2. Miller, A.J.; Mihm, M.C. Melanoma. N. Engl. J. Med, 2006, 355(1), 51-65.
3. Elder, D.E. Pathology of melanoma. Clin. Cancer Res., 2006, 12(7), 2308s-2311s.
4. Marks, R. Epidemiology of melanoma. Clin. Exp. Dermatol., 2000, 25(6), 459-463.
5. Soengas, M.S.; Lowe, S.W. Apoptosis and melanoma chemoresistance. Oncogene, 2003, 22(20), 3138-3151.
6. Tarhini, A.A.; Agarwala, S.S. Cutaneous melanoma: available therapy for metastatic disease. Dermatol. Ther., 2006, 19(1), 19-25.
7. Taran, J.M.; Heenan, P.J. Clinical and histologic features of level 2 cutaneous malignant melanoma associated with metastasis. Cancer, 2001, 91(9), 1822-1825.
8. Balch, C.M.; Soong, S.J.; Gershenwald, J.E.; Thompson, J.F.; Reintgen, D.S.; Cascinelli, N.; Urist, M.; McMasters, K.M.; Ross, M.I.; Kirkwood, J.M.; Atkins, M.B.; Thompson, J.A.; Coit, D.G.; Byrd, D.; Desmond, R.; Zhang, Y.; Liu, P.Y.; Lyman, G.H.; Morabito, A. Prognostic factors analysis of 17600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J. Clin. Oncol., 2001, 19(16), 3622-3634.
9. Gray-Schopfer, V.; Wellbrock, C.; Marais, R. Melanoma biology and new targeted therapy. Nature, 2007, 445(7130), 851-857.
10. Stahl, J.M; Sharma, A.; Cheung, M.; Zimmerman, M.; Cheng, J.Q.; Bosenberg, M.W.; Kester, M.; Sandirasegarane, L.; Robertson, G.P. Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Res., 2004, 64(19), 7002-7010.
11. Weber, L.; Kirsch, E.; Muller, P.; Krieg, T. Collagen type distribution and macromolecular organization of connective tissue in different layers of human skin. J. Invest. Dermatol., 1984, 82(2), 156-160.
12. Garrone, R.; Lethias, C.; Le Guellec, D. Distribution of minor collagens during skin development. Microsc. Res. Tech., 1997, 38(4), 407-412.
13. Ntayi, C.; Lorimier, S.; Berthier-Vergnes, O.; Hornebeck, W.; Bernard, P. Cumulative influence of matrix metalloproteinase-1 and -2 in the migration of melanoma cells within three-dimensional type I collagen lattices. Exp. Cell Res., 2001, 270(1), 110-118.
14. Baer, S.C.; Schultz, D.; Synnestvedt, M.; Elder, D.E. Desmoplasia and neurotropism. Prognostic variables in patients with stage I melanoma. Cancer, 1995, 76(11), 2242-2247.
15. Busam, K.J.; Zhao, H.; Coit, D.G.; Kucukgol, D.; Jungbluth, A.A.; Nobrega, J.; Viale, A. Distinction of desmoplastic melanoma from non-desmoplastic melanoma by gene expression profiling. J. Invest. Dermatol., 2005, 124(2), 412-418.
16. Hawkins, W.G.; Busam, K.J.; Ben-Porat, L.; Panageas, K.S.; Coit, D.G.; Gyorki, D.E.; Linehan, D.C.; Brady, M.S. Desmoplastic melanoma: a pathologically and clinically distinct form of cutaneous melanoma. Ann. Surg. Oncol., 2005, 12(3), 207-213.
17. Spatz, A.; Shaw, H.M.; Crotty, K.A.; Thompson, J.F.; McCarthy, W.H. Analysis of histopathological factors associated with prolonged survival of 10 years or more for patients with thick melanomas (> 5 mm). Histopathology, 1998, 33(5), 406-413.
18. Quinn, M.J.; Crotty, K.A.; Thompson, J.F.; Coates, A.S.; O'Brien, C.J.; McCarthy, W.H. Desmoplastic and desmoplastic neurotropic melanoma: experience with 280 patients. Cancer, 1998, 83(6), 1128-1135.
19. van Kempen, L.C.; van Muijen, G.N.; Ruiter, D.J. Melanoma progression in a changing environment. Eur. J. Cell Biol., 2007, 86(2), 65-67.
20. van Kempen, L.C.; Rijntjes, J.; Marmor-Cornelissen, I.; Vincent-Naulleau, S.; Gerritsen, M.J.; Ruiter, D.J.; van Dijk, M.C.; Geffrotin, C.; van Muijen, G.N. Type I collagen expression contributes to angiogenesis and the development of deeply invasive cutaneous melanoma. Int. J. Cancer, 2008, 122(5), 1019-1029.
21. Hornebeck, W.; Derouette, J.C.; Brechemier, D.; Adnet, J.J.; Robert, L. Elastogenesis and elastinolytic activity in human breast cancer. Biomedicine, 1977, 26(1), 48-52.
22. Henriet, P.; Zhong, Z.D.; Brooks, P.C.; Weinberg, K.I.; DeClerck, Y.A. Contact with fibrillar collagen inhibits melanoma cell proliferation by up-regulating p27KIP1. Proc. Natl. Acad. Sci. USA, 2000, 97(18), 10026-10031.
23. Wall, S.J.; Werner, E.; Werb, Z.; DeClerck, Y.A. Discoidin domain receptor 2 mediates tumor cell cycle arrest induced by fibrillar collagen. J. Biol. Chem., 2005, 280(48), 40187-40194.
24. Wall, S.J.; Zhong, Z.D.; DeClerck, J.A. The cyclin-dependent kinase inhibitors p15INK4B and p21CIP1 are critical regulators of fibrillar collagen-induced tumor cell cycle arrest. J. Biol. Chem., 2007, 282(33), 24471-24476.
25. Seftor, E.A.; Meltzer, P.S.; Kirschmann, D.A.; Margaryan, N.V.; Seftor, R.E.; Hendrix, M.J. The epigenetic reprogramming of poorly aggressive melanoma cells by a metastatic microenvironment. J. Cell. Mol. Med., 2006, 10(1), 174-196.
26. Hornebeck, W.; Maquart, F.X. Proteolyzed matrix as a template for the regulation of tumor progression. Biomed. Pharmacother., 2003, 57(5-6), 223-230.
27. Gaggar, A.; Jackson, P.L.; Noerager, B.D.; O'Reilly, P.J.; McQuaid, D.B.; Rowe, S.M.; Clancy, J.P.; Blalock, J.E.; A novel proteolytic cascade generates an extracellular matrix-derived chemoattractant in chronic neutrophilic inflammation. J. Immunol., 2008, 180(8), 5662-5669.
28. Postovit, L.M.; Seftor, E.A.; Seftor, R.E.; Hendrix, M.J. Influence of the microenvironment on melanoma cell fate determination and phenotype. Cancer Res., 2006, 66(16), 7833-7836.
29. Rich, A.; Crick, F.H. The molecular structure of collagen. J. Mol. Biol., 1961, 3, 483-506.
30. Kramer, R.Z.; Bella, J.; Brodsky, B.; Berman, H.M.; The crystal and molecular structure of a collagen-like peptide with a biologically relevant sequence. J. Mol. Biol., 2001, 311(1), 131-147.
31. Orgel, J.P.; Irving, T.C.; Miller, A.; Wess, T.J. Microfibrillar structure of type I collagen in situ. Proc. Natl. Acad. Sci USA, 2006, 103(24), 9001-9005.
32. Prockop, D.J.; Kivirikko, K.I. Collagens: molecular biology, diseases, and potentials for therapy. Annu. Rev. Biochem., 1995, 64, 403-434.
33. Sakai, T.; Gross, J. Some properties of the products of reaction of tadpole collagenase with collagen. Biochemistry, 1967, 6(2), 518-528.
34. Krane, S.M. The importance of proline residues in the structure, stability and susceptibility to proteolytic degradation of collagens. Amino Acids, 2008, 35(4), 703-710.
35. Woessner, J.F.; Nagase, H. Matrix Metalloproteinases and TIMPs, Oxford University Press: Oxford, UK, 2000.
36. Sternlicht, M.D.; Werb, Z. How matrix metalloproteinases regulate cell behavior. Annu. Rev. Cell Dev. Biol., 2001, 17, 463-516.
37. Chung, L.; Dinakarpandian, D.; Yoshida, N.; Lauer-Fields, J.L.; Fields, G.B.; Visse, R.; Nagase, H. Collagenase unwinds triple-helical collagen prior to peptide bond hydrolysis. EMBO J., 2004, 23(15), 3020-3030.
38. Clark, I.M.; Cawston, T.E. Fragments of human fibroblast collagenase: purification and characterisation. Matrix Suppl., 1992, 1, 73.
39. Overall, C.M. Molecular determinants of metalloproteinase substrate specificity: matrix metalloproteinase substrate binding domains, modules, and exosites. Mol. Biotechnol., 2002, 22(1), 51-86.
40. Tam, E.M.; Moore, T.R.; Butler, G.S.; Overall, C.M. Characterization of the distinct collagen binding, helicase and cleavage mechanisms of matrix metalloproteinase 2 and 14 (gelatinase A and MT1-MMP): the differential roles of the MMP hemopexin c domains and the MMP-2 fibronectin type II modules in collagen triple helicase activities. J. Biol. Chem., 2004, 279(41), 43336-43344.
41. Jozic, D.; Bourenkov, G.; Lim, N.H.; Visse, R.; Nagase, H.; Bode, W.; Maskos, K. X-ray structure of human proMMP-1: new insights into procollagenase activation and collagen binding. J. Biol. Chem., 2005, 280(10), 9578-9585.
42. De Souza, S.J.; Pereira, H.M.; Jacchieri, S.; Brentani, R.R. Collagen/ collagenase interaction: does the enzyme mimic the conformation of its own substrate? FASEB J., 1996, 10(8), 927-930.
43. Chung, L.; Shimokawa, K.; Dinakarpandian, D.; Grams, F.; Fields, G.B.; Nagase, H. Identification of the (183)RWTNNFREY(191) region as a critical segment of matrix metalloproteinase 1 for the expression of collagenolytic activity. J. Biol. Chem., 2000, 275(38), 29610-29617.
44. Perumal, S.; Antipova, O.; Orgel, J.P. Collagen fibril architecture, domain organization, and triple-helical conformation govern its proteolysis. Proc. Natl Acad. Sci. USA, 2008, 105(8), 2824-2829.
45. Tam, E.M.; Wu, Y.I.; Butler, G.S.; Stack, M.S.; Overall, C.M. Collagen binding properties of the membrane type-1 matrix metalloproteinase (MT1-MMP) hemopexin C domain. The ectodomain of the 44-kDa autocatalytic product of MT1-MMP inhibits cell invasion by disrupting native type I collagen cleavage. J. Biol. Chem., 2002, 277(41), 39005-39014.
46. Knäuper, V.; Docherty, A.J.; Smith, B.; Tschesche, H.; Murphy, G. Analysis of the contribution of the hinge region of human neutrophil collagenase (HNC, MMP-8) to stability and collagenolytic activity by alanine scanning mutagenesis. FEBS Lett., 1997, 405(1), 60-64.
47. Gioia, M.; Monaco, S.; Fasciglione, G.F.; Coletti, A.; Modesti, A.; Marini, S.; Coletta, M. Characterization of the mechanisms by which gelatinase A, neutrophil collagenase, and membrane-type metalloproteinase MMP-14 recognize collagen I and enzymatically process the two alpha-chains. J. Mol. Biol., 2007, 368(4), 1101-1113.
48. Leikina, E.; Mertts, M.V.; Kuznetsova, N.; Leikin, S. Type I collagen is thermally unstable at body temperature. P roc. Natl. Acad. Sci. USA, 2002, 99(3), 1314-1318.
49. Stultz, C.M. Localized unfolding of collagen explains collagenase cleavage near imino-poor sites. J. Mol. Biol., 2002, 319(5), 997-1003.
50. Jaisson, S.; Lorimier, S.; Ricard-Blum, S.; Sockalingum, G.D.; Delevallée-Forte, C.; Kegelaer, G.; Manfait, M.; Garnotel, R.; Gillery, P. Impact of carbamylation on type I collagen conformational structure and its ability to activate human polymorphonuclear neutrophils. Chem. Biol., 2006, 13(2), 149-159.
51. Jaisson, S.; Larreta-Garde, V.; Bellon, G.; Hornebeck, W.; Garnotel, R.; Gillery, P. Carbamylation differentially alters type I collagen sensitivity to various collagenases. Matrix Biol., 2007, 26(3), 190-196.
52. Maddodi, N.; Setaluri, V. Role of UV in cutaneous melanoma. Photochem. Photobiol., 2008, 84(2), 528-536.
53. Miles, C.A.; Sionkowska, A.; Hulin, S.L.; Sims, T.J.; Avery, N.C.; Bailey, A.J. Identification of an intermediate state in the helix-coil degradation of collagen by ultraviolet light. J. Biol. Chem., 2000, 275(42), 33014-33020.
54. Menter, J.M.; Cornelison, L.M.; Cannick, L.; Patta, A.M.; Dowdy, J.C.; Sayre, R.M.; Abukhalaf, I.K.; Silvestrov, N.S.; Willis, I. Effect of UV on the susceptibility of acid-soluble Skh-1 hairless mouse collagen to collagenase. Photodermatol. Photoimmunol. Photomed., 2003, 19(1), 28-34.
55. Egeblad, M.; Shen, H.C.J.; Behonick, D.J.; Wilmes, L.; Eichten, A.; Korets, L.V.; Kheradmand, F.; Werb, Z.; Coussens, L.M. Type I collagen is a genetic modifier of matrix metalloproteinase 2 in murine skeletal development. Dev. Dyn., 2007, 236(6), 1683-1693.
56. Hernandez-Barrantes, S.; Bernardo, M.; Toth, M.; Fridman, R. Regulation of membrane type-matrix metalloproteinases. Semin. Cancer Biol., 2002, 12(2), 131-138.
57. Yana, I.; Weiss, S.J. Regulation of membrane type-1 matrix metalloproteinase activation by proprotein convertases. Mol. Biol. Cell, 2000, 11(7), 2387-2401.
58. Itoh, Y.; Takamura, A.; Ito, N.; Maru, Y.; Sato, H.; Suenaga, N.; Aoki, T.; Seiki, M. Homophilic complex formation of MT1-MMP facilitates proMMP-2 activation on the cell surface and promotes tumor cell invasion. EMBO J., 2001, 20(17), 4782-4793.
59. Itoh, Y.; Ito, N.; Nagase, H.; Evans, R.D.; Bird, S.A.; Seiki, M. Cell surface collagenolysis requires homodimerization of the membrane-bound collagenase MT1-MMP. Mol. Biol. Cell, 2006, 17(12), 5390-5399.
60. Ellerbroek, S.M.; Wu, Y.I.; Overall, C.M.; Stack, M.S. Functional interplay between type I collagen and cell surface matrix metalloproteinase activity. J. Biol. Chem., 2001, 276(27), 24833-24842.
61. Stricker, T.P.; Dumin, J.A.; Dickeson, S.K.; Chung, L.; Nagase, H.; Parks, W.C.; Santoro, S.A. Structural analysis of the alpha(2) integrin I domain/procollagenase-1 (matrix metalloproteinase-1) interaction. J. Biol. Chem., 2001, 276(31), 29375-29381.
62. Brooks, P.C.; Strömblad, S.; Sanders, L.C.; von Schalscha, T.L.; Aimes, R.T.; Stetler-Stevenson, W.G.; Quigley, J.P.; Cheresh, D.A. Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3. Cell, 1996, 85(5), 683-693.
63. Emonard, H.; Bellon, G.; de Diesbach, P.; Mettlen, M.; Hornebeck, W.; Courtoy, P.J. Regulation of matrix metalloproteinase (MMP) activity by the low-density lipoprotein receptor-related protein (LRP). A new function for an "old friend". Biochimie, 2005, 87(3-4), 369-376.
64. Curino, A.C.; Engelholm, L.H.; Yamada, S.S.; Holmbeck, K.; Lund, L.R.; Molinolo, A.A.; Behrendt, N.; Nielsen, B.S.; Bugge, T.H. Intracellular collagen degradation mediated by uPARAP/Endo180 is a major pathway of extracellular matrix turnover during malignancy. J. Cell Biol., 2005, 169(6), 977-985.
65. Madsen, D.H.; Engelholm, L.H.; Ingvarsen, S.; Hillig, T.; Wagenaar-Miller, R.A.; Kjoller, L.; Gardsvoll, H.; Hoyer-Hansen, G.; Holmbeck, K.; Bugge, T.H.; Behrendt, N. Extracellular collagenases and the endocytic receptor, urokinase plasminogen activator receptor-associated protein/Endo180, cooperate in fibroblast-mediated collagen degradation. J. Biol. Chem., 2007, 282(37), 27037-27045.
66. Lee, H.; Overall, C.M.; Mc Culloch, C.A.; Sodek, J. A critical role for the membrane-type 1 matrix metalloproteinase in collagen phagocytosis. Mol. Biol. Cell, 2006, 17(11), 4812-4826.
67. Wagenaar-Miller, R.A.; Engelholm, L.H.; Gavard, J.; Yamada, S.S.; Gutkind, J.S.; Behrendt, N.; Bugge, T.H.; Holmbeck, K. Complementary roles of intracellular and pericellular collagen degradation pathways in vivo. Mol. Cell. Biol., 2007, 27(18), 6309-6322.
68. Minn, A.J.; Kang, Y.; Serganova, I.; Gupta, G.P.; Giri, D.D.; Doubrovin, M.; Ponomarev, V.; Gerald, W.L.; Blasberg, R.; Massagué, J. Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors. J. Clin. Invest., 2005, 115(1), 44-55.
69. Balbin, M.; Fueyo, A.; Tester, A.M.; Pendas, A.M.; Pitiot, A.S.; Astudillo, A.; Overall, C.M.; Shapiro, S.D.; Lopez-Otin, C. Loss of collagenase-2 confers increased skin tumor susceptibility to male mice. Nat. Genet., 2003, 35(3), 252-257.
70. Gutierrez-Hernandez, A.; Fueyo, A.; Folgueras, A.R.; Garabaya, C.; Pennington, C.J.; Pilgrim, S.; Edwards, D.R.; Holliday, D.L.; Jones, J.L.; Span, P.N.; Sweep, F.C.G.J.; Puente, X.S.; Lopez-Otin, C. Matrix metalloproteinase-8 functions as a metastasis suppressor through modulation of tumor cell adhesion and invasion. Cancer Res., 2008, 68(8), 2755-2763.
71. Overall, C.M.; Kleifeld, O. Validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev. Cancer, 2006, 6(3), 227-239.
72. Hofmann, U.B.; Houben, R.; Brocker, E.B.; Becker, J.C. Role of matrix metalloproteinases in melanoma cell invasion. Biochimie, 2005, 87(3-4), 307-314.
73. Nikkola, J.; Vihinen, P.; Vlaykova, T.; Hahka-Kemppinen, M.; Kahari, V.M.; Pyrhonen, S. High collagenase-1 expression correlates with a favourable chemoimmunotherapy response in human metastatic melanoma. Melanoma Res., 2001, 11(2), 157-166.
74. Airola, K.; Karonen, T.; Vaalamo, M.; Lehti, K.; Lohi, J.; Kariniemi, A.L.; Keski-Oja, J.; Saarialho-Kere, U.K. Expression of collagenases-1 and -3 and their inhibitors TIMP-1 and -3 correlates with the level of invasion in malignant melanomas. Br. J. Cancer, 1999, 80(5-6), 733-743.
75. Nikkola, J.; Vihinen, P.; Vlaykova, T.; Hahka-Kemppinen, M.; Kahari, V.M.; Pyrhonen, S. High expression levels of collagenase-1 and stromelysin-1 correlate with shorter disease-free survival in human metastatic melanoma. Int. J. Cancer, 2002, 97(4), 432-438.
76. Nikkola, J.; Vihinen, P.; Vuoristo, M.S.; Kellokumpu-Lehtinen, P.; Kahari, V.M.; Pyrhonen, S. High serum levels of matrix metalloproteinase-9 and matrix metalloproteinase-1 are associated with rapid progression in patients with metastatic melanoma. Clin. Cancer Res., 2005, 11(14), 5158-5166.
77. Rutter, J.L.; Mitchell, T.I.; Buttice, G.; Meyers, J.; Gusella, J.F.; Ozelius, L.J.; Brinckerhoff, C.E.; A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter creates an Ets binding site and augments transcription. Cancer Res., 1998, 58(23), 5321-5325.
78. Benbow, U.; Tower, G.B.; Wyatt, C.A.; Buttice, G.; Brinckerhoff, C.E. High levels of MMP-1 expression in the absence of the 2G single nucleotide polymorphism is mediated by p38 and ERK1/2 mitogen-activated protein kinases in VMM5 melanoma cells. J. Cell. Biochem., 2002, 86(2), 307-319.
79. Huntington, J.T.; Shields, J.M.; Der, C.J.; Wyatt, C.A.; Benbow, U.; Slingluff, C.L.; Brinckerhoff, C.E. Overexpression of collagenase 1 (MMP-1) is mediated by the ERK pathway in invasive melanoma cells: role of BRAF mutation and fibroblast growth factor signaling. J. Biol. Chem., 2004, 279(32), 33168-33176.
80. Blackburn, J.S.; Rhodes, C.H.; Coon, C.I.; Brinckerhoff, C.E.; RNA interference inhibition of matrix metalloproteinase-1 prevents melanoma metastasis by reducing tumor collagenase activity and angiogenesis. Cancer Res., 2007, 67(22), 10849-10858.
81. Vaisanen, A.; Tuominen, H.; Kallioinen, M.; Turpeenniemi-Hujanen, T. Matrix metalloproteinase-2 (72 kD type IV collagenase) expression occurs in the early stage of human melanocytic tumour progression and may have prognostic value. J. Pathol., 1996, 180(3), 283-289.
82. Vaisanen, A.; Kallioinen, M.; Turpeenniemi-Hujanen, T. Comparison of the prognostic value of matrix metalloproteinases 2 and 9 in cutaneous melanoma. Hum. Pathol., 2008, 39(3), 377-385.
83. Kurschat, P.; Wickenhauser, C.; Groth, W.; Krieg, T.; Mauch, C. Identification of activated matrix metalloproteinase-2 (MMP-2) as the main gelatinolytic enzyme in malignant melanoma by in situ zymography. J. Pathol., 2002, 197(2), 179-187.
84. Ntayi, C.; Labrousse, A.L.; Debret, R.; Birembaut, P.; Bellon, G.; Antonicelli, F.; Hornebeck, W.; Bernard, P. Elastin-derived peptides upregulate matrix metalloproteinase-2-mediated melanoma cell invasion through elastin-binding protein. J. Invest. Dermatol., 2004, 122(2), 256-265.
85. Hofmann, U.B.; Eggert, A.A.; Blass, K.; Brocker, E.B.; Becker, J.C. Expression of matrix metalloproteinases in the microenvironment of spontaneous and experimental melanoma metastases reflects the requirements for tumor formation. Cancer Res., 2003, 63(23), 8221-8225.
86. Itoh, T.; Tanioka, M.; Yoshida, H.; Yoshioka, T.; Nishomoto, H.; Itohara, S. Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res., 1998, 58(5), 1048-1051.
87. Hofmann, U.B.; Westphal, J.R.; Zendman, A.J.; Becker, J.C.; Ruiter, D.J.; van Muijen, G.N. Expression and activation of matrix metalloproteinase-2 (MMP-2) and its co-localization with membrane-type 1 matrix metalloproteinase (MT1-MMP) correlate with melanoma progression. J. Pathol., 2000, 191(3), 245-256.
88. Minond, D.; Lauer-Fields, J.L.; Cudic, M.; Overall, C.M.; Pei, D.; Brew, K.; Moss, M.L.; Fields, G.B. Differentiation of secreted and membrane-type matrix metalloproteinase activities based on substitutions and interruptions of triple-helical sequences. Biochemistry, 2007, 46(12), 3724-3733.
89. Holmbeck, K.; Bianco, P.; Caterina, J.; Yamada, S.; Kromer, M.; Kuznetsov, S.A.; Mankani, M.; Robey, P.G.; Poole, A.R.; Pidoux, I.; Ward, J.M.; Birkedal-Hansen, H. MT1-MMP-deficient mice develop dwarfism, osteopenia, arthritis, and connective tissue disease due to inadequate collagen turnover. Cell, 1999, 99(1), 81-92.
90. Sabeh, F.; Ota, I.; Holmbeck, K.; Birkedal-Hansen, H.; Soloway, P.; Balbin, M.; Lopez-Otin, C.; Shapiro, S.; Inada, M.; Krane, S.; Allen, E.; Chung, D.; Weiss, S.J. Tumor cell traffic through the extra-cellular matrix is controlled by the membrane-anchored collagenase MT1-MMP. J. Cell. Biol., 2004, 167(4), 769-781.
91. Hotary, K.B.; Allen, E.D.; Brooks, P.C.; Datta, N.S.; Long, M.W.; Weiss, S.J. Membrane type I matrix metalloproteinase usurps tumor growth control imposed by the three-dimensional extra-cellular matrix. Cell, 2003, 114(1), 33-45.
92. Itoh, Y.; Seiki, M. MT1-MMP: a potent modifier of pericellular microenvironment. J. Cell. Physiol., 2006, 206(1), 1-8.
93. Lafleur, M.A.; Mercuri, F.A.; Ruangpanit, N.; Seiki, M.; Sato, H.; Thompson, E.W.; Type I collagen abrogates the clathrin-mediated internalization of membrane type 1 matrix metalloproteinase (MT1-MMP) via the MT1-MMP hemopexin domain. J. Biol. Chem., 2006, 281(10), 6826-6840.
94. Itoh, Y.; Ito, N.; Nagase, H.; Seiki, M. The second dimer interface of MT1-MMP, the transmembrane domain, is essential for ProMMP-2 activation on the cell surface. J. Biol. Chem., 2008, 283(19), 13053-13062.
95. Nyalendo, C.; Beaulieu, E.; Sartelet, H.; Michaud, M.; Fontaine, N.; Gingras, D.; Béliveau, R. Impaired tyrosine phosphorylation of membrane type 1-matrix metalloproteinase reduces tumor cell proliferation in three-dimensional matrices and abrogates tumor growth in mice. Carcinogenesis, 2008, 29(8), 1655-1664.
96. Li, X.Y.; Ota, I.; Yana, I.; Sabeh, F.; Weiss, S.J. Molecular dissection of the structural machinery underlying the tissue-invasive activity of membrane type-1 matrix metalloproteinase. Mol. Biol. Cell, 2008, 19(8), 3221-3233.
97. Hornebeck, W.; Emonard, H. In Encyclopedic Reference of Vascular Biology and Pathology; Bikfalvi A., Ed.; Springer-Verlag: Berlin, Heidelberg, New York, 2000; pp. 300-304.
98. Brew, K.; Dinakarpandian, D.; Nagase, H. Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim. Biophys. Acta, 2000, 1477(1-2), 267-283.
99. de Lorenzo, M.S.; Ripoll, G.V.; Yoshiji, H.; Yamazaki, M.; Thorgeirsson, U.P.; Alonso, D.F.; Gomez, D.E. Altered tumor angiogenesis and metastasis of B16 melanoma in transgenic mice over-expressing tissue inhibitor of metalloproteinases-1. In Vivo, 2003, 17(1), 45-50.
100. Valente, P.; Fassina, G.; Melchiori, A.; Masiello, L.; Cilli, M.; Vacca, A.; Onisto, M.; Santi, L.; Stetler-Stevenson, W.G.; Albini, A. TIMP-2 over-expression reduces invasion and angiogenesis and protects B16F10 melanoma cells from apoptosis. Int. J. Cancer, 1998, 75(2), 246-253.
101. Ahonen, M.; Poukkula, M.; Baker, A.H.; Kashiwagi, M.; Nagase, H.; Eriksson, J.E.; Kahari, V.M.; Tissue inhibitor of metalloproteinases-3 induces apoptosis in melanoma cells by stabilization of death receptors. Oncogene, 2003, 22(14), 2121-2134.
102. Cruz-Munoz, W.; Sanchez, O.H.; Di Grappa, M.; English, J.L.; Hill, R.P.; Khokha, R. Enhanced metastatic dissemination to multiple organs by melanoma and lymphoma cells in timp-3-/- mice. Oncogene, 2006, 25(49), 6489-6496.
103. Quirt, I.; Bodurth, A.; Lohmann, R.; Rusthoven, J.; Belanger, K.; Young, V.; Wainman, N.; Stewar, W.; Eisenhauer, E.; National Cancer Institute of Canada Clinical Trial Group, Phase II study of marimastat (BB-2516) in malignant melanoma: a clinical and tumor biopsy study of the National Cancer Institute of Canada Clinical Trials Group. Invest. New Drugs, 2002, 20(4), 431-437.
104. Coussens, L.M.; Fingleton, B.; Matrisian, L.M. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science, 2002, 295(5564), 2387-2392.
105. Mannello, F.; Tonti, G.; Papa, S. Matrix metalloproteinase inhibitors as anticancer therapeutics. Curr. Cancer Drug Targets, 2005, 5(4), 285-298.
106. Nuti, E.; Tuccinardi, T.; Rossello, A. Matrix metalloproteinase inhibitors: new challenges in the era of post broad-spectrum inhibitors. Curr. Pharm. Des., 2007, 13(20), 2087-2100.
107. Whittaker, M.; Floyd, C.D.; Brown, P.; Gearing, A.J.H. Design and therapeutic application of matrix metalloproteinase inhibitors. Chem. Rev., 1999, 99(9), 2735-2776.
108. Fisher, J.F.; Mobashery, S. Recent advances in MMP inhibitor design. Cancer Metastasis Rev., 2006, 25(1), 115-136.
109. Nuti, E.; Tuccinardi, T.; Rossello, A. Matrix metalloproteinase inhibitors: New challenges in the era of post broad-spectrum inhibitors. Curr. Pharm. Des., 2007, 13(20), 2087-2100.
110. Fingleton, B. MMPs as therapeutic targets - Still a viable option? Semin. Cell Dev. Biol., 2008, 19, 61-68.
111. Rao, G.B. Recent developments in the design of specific matrix metalloproteinase inhibitors aided by structural and computational studies. Curr. Pharm. Des., 2005, 11(3), 295-322.
112. Fingleton, B. Matrix metalloproteinases as valid clinical targets. Curr. Pharm. Des., 2007, 13(3), 333-346.
113. Kontogiorgis, C. A.; Papaioannou, P.; Hadjipavlou-Litina, D. J. Matrix metalloproteinase inhibitors: a review on pharmacophore mapping and (Q)SARs results. Curr. Med. Chem., 2005, 12(3), 339-355.
114. Lovejoy, B.; Hassell, A.M.; Luther, M.A.; Weigl, D.; Jordan, S.R. Crystal structures of recombinant 19-kDa human fibroblast collagenase complexed to itself. Biochemistry, 1994, 33(27), 8207-8217.
115. Toba, S.; Damodaran, K.V.; Jr. Merz, K.M. Binding preferences of hydroxamate inhibitors of the matrix metalloproteinase human fibroblast collagenase. J. Med. Chem., 1999, 42(7), 1225-1234.
116. Hernick, M.; Fierke, C.A. Zinc hydrolases: the mechanisms of zinc-dependent deacetylases. Arch. Biochem. Biophys., 2005, 433(1), 71-84.
117. Augé, F.; Hornebeck, W.; Decarme, M.; Laronze, J.-Y. Improved gelatinase A selectivity by novel zinc binding groups containing galardin derivatives. Bioorg. Med. Chem. Lett., 2003, 13(10), 1783-1786.
118. Makaritis, A.; Georgiadis, D.; Dive, V.; Yiotakis, A. Diastereoselective solution and multipin-based combinatorial array synthesis of a novel class of potent phosphinic metalloprotease inhibitors. Chem. Eur. J., 2003, 9(9), 2079-2094.
119. Jacobsen, F.E.; Lewis, J.A.; Cohen, S.M. The design of inhibitors for medicinally relevant metalloproteins. ChemMedChem, 2007, 2(2), 152-171.
120. Puerta, D.T.; Cohen, S.M. Examination of novel zinc-binding groups for use in matrix metalloproteinase inhibitors. Inorg. Chem., 2003, 42(11), 3423-3430.
121. Farkas, E.; Katz, Y.; Bhusare, S.; Reich, R.; Röschenthaler, G.V.; Königsmann, M.; Breuer, E. Carbamoylphosphonate-based matrix metalloproteinase inhibitor metal complexes: solution studies and stability constants. Towards a zinc-selective binding group. J. Biol. Inorg. Chem., 2004, 9(3), 307-315.
122. Hu, X.; Shelver, W.H. Docking studies of matrix metalloproteinase inhibitors: zinc parameter optimization to improve the binding free energy prediction. J. Mol. Graph. Model. 2003, 22(2), 115-126.
123. Cheng, F.; Zhang, R.; Luo, X.; Shen, J.; Li, X.; Gu, J.; Zhu, W.; Shen, J.; Sagi, I.; Ji, R.; Chen, K.; Jiang, H. Quantum chemistry study on the interaction of the exogenous ligands and the catalytic zinc ion in matrix metalloproteinases. J. Phys. Chem. B, 2002, 106(17), 4552-4559.
124. Brown, S.; Bernardo, M.M.; Li, Z.-H.; Kotra, L.P.; Tanaka, Y.; Fridman, R.; Mobashery, S. Potent and selective mechanism-based inhibition of gelatinases. J. Am. Chem. Soc., 2000, 122(28), 6799-6800.
125. Ikejiri, M.; Bernardo, M.M.; Bonfil, R.D.; Toth, M.; Chang, M.; Fridman, R.; Mobashery, S. Potent mechanism-based inhibitors for matrix metalloproteinases. J. Biol. Chem., 2005, 280(40), 33992-34002.
126. Cuniasse, P.; Devel, L.; Makaritis, A.; Beau, F.; Georgiadis, D.; Matziari, M.; Yiotakis, A.; Dive, V. Future challenges facing the development of specific active-site-directed synthetic inhibitors of MMPs. Biochimie, 2005, 87(3-4), 393-402.
127. Nicolotti, O.; Miscioscia, T.F.; Leonetti, F.; Muncipinto, G.; Carotti, A. Screening of matrix metalloproteinases available from the protein data bank: insights into biological functions, domain organization, and zinc binding groups. J. Chem. Inf. Model., 2007, 47(6), 2439-2448.
128. Chen, J.M.; Nelson, F.C.; Levin, J.I.; Mobilio, D.; Moy, F.J.; Nilakantan, R.; Zask, A.; Powers, R. Structure-based design of a novel, potent, and selective inhibitor for MMP-13 Utilizing NMR spectroscopy and computer-aided molecular design. J. Am. Chem. Soc., 2000, 122(40), 9648-9654.
129. Terp, G.E.; Cruciani, G.C.; Christensen, I.T.; Jørgensen, F. S. Structural differences of matrix metalloproteinases with potential implications for inhibitor selectivity examined by the GRID/CPCA approach. J. Med. Chem., 2002, 45(13), 2675-2684.
130. Borkakoti, N. Structural studies of matrix metalloproteinases. J. Mol. Med. 2000, 78(5), 261-268.
131. Chen, E.I.; Li, W.; Godzik, A.; Howard, E.W.; Smith, J.W. A residue in the S2 subsite controls substrate selectivity of matrix metalloproteinase-2 and matrix metalloproteinase-9. J. Biol. Chem., 2003, 278(19), 17158-17163.
132. Broadhurst, M.J.; Brown, P.A.; Lawton, G.; Ballantyne, N.; Borkakoti, N.; Bottomley, K.M.K.; Cooper, M.I.; Eatherton, A.J.; Kilford, I.R.; Malsher, P.J.; Nixon, J.S.; Lewis, E.J.; Sutton, B.M.; Johnson, W.H. Design and synthesis of the cartilage protective agent (CPA, Ro32-3555). Bioorg. Med. Chem. Lett., 1997, 7(17), 2299-2302.
133. Beckett, R.P.; Martin, F.M.; Miller, A.; Todd, R.S.; Whittaker, M. PCT Patent Application WO9817655, 1998.; Chem. Abstr., 1999, 128, 308398.
134. Sawa, M.; Kondo, H.; Nishimura, S-I. Encounter with unexpected collagenase-1 selective inhibitor: Switchover of inhibitor binding pocket induced by fluorine atom. Bioorg. Med. Chem. Lett., 2002, 12(4), 581-584.
135. Skiles, J.W.; Gonnella, N.C.; Jeng, A.Y. The design, structure, and clinical update of small molecular weight matrix metalloproteinase inhibitors. Curr. Med. Chem., 2004, 11(22), 2911-2977.
136. Li, J.J.; Nahra, J.; Johnson, A.R.; Bunker, A.; O'Brien, P.; Yue, W-S.; Ortwine, D.F.; Man, C-F.; Baragi, V.; Kilgore, K.; Dyer, R.D.; Han, H-K. Quinazolinones and pyrido[3,4-d]pyrimidin-4-ones as orally active and specific matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis. J. Med. Chem., 2008, 51(4), 835-841.
137. Engel, C.K.; Pirard, B.; Schimanski, S.; Kirsch, R.; Habermann, J.; Klingler, O.; Schlotte, V.; Weithmann, K.U.; Wendt, K.U. Structural basis for the highly selective inhibition of MMP-13. Chem. Biol., 2005, 12(2), 181-189.
138. Breuer, E.; Frant, J.; Reich, R. Recent non-hydroxamate matrix metalloproteinase inhibitors. Expert Opin. Ther Pat., 2005, 15(3), 253-269.
139. Li, J.; Rush, III, T.S.; Li, W.; DeVincentis, D.; Du, X.; Hu, Y.; Thomason, J.R.; Xiang, J.S.; Skotnicki, J.S.; Tam, S.; Cunningham, K.M.; Chockalingam, P.S.; Morris, E.A.; Levin, J.I. Synthesis and SAR of highly selective MMP-13 inhibitors. Bioorg. Med. Chem. Lett., 2005, 15(22), 4961-4966.
140. Reiter, L.A.; Freeman-Cook, K.D.; Jones, C.S.; Martinelli, G.J.; Antipas, A.S.; Berliner, M.A.; Datta, K.; Downs, J.T.; Eskra, J.D.; Forman, M.D.; Greer, E.M.; Guzman, R.; Hardink, J.R.; Janat, F.; Keene, N.F.; Laird, E.R.; Liras, J.L.; Lopresti-Morrow, L.L.; Mitchell, P.G.; Pandit, J.; Robertson, D.; Sperger, D.; Vaughn-Bowser, M.L.; Waller, D.M.; Yocum, S.A. Potent, selective pyrimidinetrione-based inhibitors of MMP-13. Bioorg. Med. Chem. Lett., 2006, 16(22), 5822-5826.
141. Blagg, J.A.; Noe, M.C.; Wolf-Gouveia, L.A.; Reiter, L.A.; Laird, E.R.; Chang, S-P.P.; Danley, D.E.; Downs, J.T.; Elliot, N.C.; Eskra, J.D.; Griffith, R.J.; Hardink, J.R.; Haugeto, A.I.; Jones, C.S.; Liras, J.L.; Lopresti-Morrow, L.L.; Mitchell, P.G.; Pandit, J.; Robinson, R.P.; Subramanyam, C.; Vaughn-Bowser, M.L.; Yocum, S.A. Potent pyrimidinetrione-based inhibitors of MMP-13 with enhanced selectivity over MMP-14. Bioorg. Med. Chem. Lett., 2005, 15(7), 1807-1810.
142. Rossello, A.; Nuti, E.; Orlandini, E.; Carelli, P.; Rapposelli, S.; Macchia, M.; Minutolo, F.; Carbonaro, L.; Albini, A.; Benelli, R.; Cercignani, G.; Murphy, G.; Balsamo, A. New N-arylsulfonyl-N-alkoxyaminoacetohydroxamic acids as selective inhibitors of gelatinase A (MMP-2). Bioorg. Med. Chem., 2004, 12(9), 2441-2450.
143. Tuccinardi, T.; Martinelli, A.; Nuti, E.; Carelli, P.; Balzano, F.; Uccello-Barretta, G.; Murphy, G.; Rossello, A. Amber force field implementation, molecular modelling study, synthesis and MMP-1/MMP-2 inhibition profile of (R)- and (S)-N-hydroxy-2-(N- isopropoxybiphenyl-4- ylsulfonamido)-3-methylbutanamides. Bioorg. Med. Chem., 2006, 14(12), 4260-4276.
144. Rossello, A.; Nuti, E.; Carelli, P.; Orlandini, E.; Macchia, M.; Nencetti, S.; Zandomeneghi, M.; Balzano, F.; Barretta, G.U.; Albini, A.; Benelli, R.; Cercignani, G.; Murphy G.; Balsamo, A. N-i-Propoxy- N-biphenylsulfonylaminobutylhydroxamic acids as potent and selective inhibitors of MMP-2 and MT1-MMP. Bioorg. Med. Chem. Lett., 2005, 15(5), 1321-1326.
145. Barta, T.E.; Becker, D.P.; Bedell, L.J.; De Crescenzo, G.A.; McDonald, J.J.; Munie, G.E.; Rao, S.; Shieh, H.-S.; Stegeman, R.; Stevens, A.M.; Villamil, C.I. Synthesis and activity of selective MMP inhibitors with an aryl backbone. Bioorg. Med. Chem. Lett., 2000, 10(24), 2815-2817.
146. Moroy, G.; Denhez, C.; El Mourabit, H.; Toribio, A.; Dassonville, A.;
147. Curtin, M.L.; Florjancic, A.S.; Heyman, H.R.; Michaelides, M.R.; Garland, R.B.; Holms, J.H.; Steinman, D.H.; Dellaria, J.F.; Gong, J.; Wada, C.K.; Guo, Y.; Elmore, I.B.; Tapang, P.; Albert, D.H.; Magoc, T.J.; Marcotte, P.A.; Bouska, J.J.; Goodfellow, C.L.; Bauch, J.L.; Marsh, K.C.; Morgan, D.W.; Davidsen, S.K. Discovery and characterization of the potent, selective and orally bioavailable MMP inhibitor ABT-770. Bioorg. Med. Chem. Lett., 2001, 11(12), 1557-1560.
148. Breuer, E.; Salomon, C.J.; Katz, Y.; Chen, W.; Lu, S.; Röschenthaler, G.-V.; Hadar, R.; Reich, R. Carbamoylphosphonates, a new class of in vivo active matrix metalloproteinase inhibitors. 1. Alkyl- and cycloalkylcarbamoylphosphonic acids. J. Med. Chem., 2004, 47(11), 2826-2832.
149. Reich, R.; Katz, Y.; Hadar, R.; Breuer, E. Carbamoylphosphonate matrix metalloproteinase inhibitors 3: in vivo evaluation of cyclopentylcarbamoylphosphonic acid in experimental metastasis and angiogenesis. Clin. Cancer Res., 2005, 11(10), 3925-3929.
150. Hoffman, A.; Quadri, B.; Frant, J.; Katz, Y.; Bhusare, S.; Breuer, E.; Hadar, R.; Reich, R. Carbamoylphosphonate matrix metalloproteinase inhibitors 6: cis-2-aminocyclohexylcarbamoylphosphonic acid, a novel orally active antimetastatic matrix metalloproteinase-2 selective inhibitor-synthesis and pharmacodynamic and pharmacokinetic analysis. J. Med. Chem., 2008, 51(5), 1406-1414.
151. Tullis, J.S.; Laufersweiler, M.J.; VanRens, J.C.; Natchus, M.G.; Bookland R.G.; Almstead, N.G.; Pikul, S.; De, B.; Hsieh, L.C.; Janusz, M.J.; Branch, T.M.; Peng, S.X.; Jin, Y.Y.; Hudlicky, T.; Oppong, K. The development of new carboxylic acid-based MMP inhibitors derived from a cyclohexylglycine scaffold. Bioorg. Med. Chem. Lett., 2001, 11(15), 1975-1979.
152. Skiles, J.W.; Gonnella, N.C.; Jeng, A.Y. The design, structure, and therapeutic application of matrix metalloproteinase inhibitors. Curr. Med. Chem., 2001, 8(4), 425-474.
153. Lee, H.-J.; Chung, M.-C.; Lee, C.-H.; Yun, B.-S.; Chun, H.-K.; Kho, Y.-H. Gelastatins A and B, new inhibitors of gelatinase A from Westerdykella multispora F50733. J. Antibiot., 1997, 50(4), 357-359.
154. Kim, E.-J.; Ko, S.-Y. Synthesis of arylidene-substituted gelastatin analogues and their screening for MMP-2 inhibitory activity. Bioorg. Med. Chem., 2005, 13(12), 4103-4112.
155. Augé, F.; Hornebeck, W.; Laronze, J-Y. A novel strategy for designing specific gelatinase A inhibitors: potential use to control tumor progression. Crit. Rev. Oncol. Hematol., 2004, 49(3), 277-282.
156. LeDour, G.; Moroy, G.; Rouffet, M.; Bourguet, E.; Guillaume, D.; Decarme, M.; ElMourabit, H.; Augé, F.; Alix, A.J.P.; Laronze, J.-Y.; Bellon, G.; Hornebeck, W.; Sapi, J. Introduction of the 4-(4-bromophenyl)benzenesulfonyl group to hydrazide analogs of Ilomastat leads to potent gelatinase B (MMP-9) inhibitors with improved selectivity. Bioorg. Med. Chem., 2008, 16(18), 8745-8759.
157. Chen, E.I.; Kridel, S.J.; Howard, E.W.; Li, W.; Godzik, A.; Smith, J.W. A unique substrate recognition profile for matrix metalloproteinase-2. J. Biol. Chem., 2002, 277(6), 4485-4491.
158. Fujita, M.; Nakao, Y.; Matsunaga, S.; Seiki, M.; Itoh, Y.; van Soest, R.W.M.; Heubes, M.; Faulkner, D.J.; Fusetani, N. Isolation and structure elucidation of two phosphorylated sterol sulfates, MT1-MMP inhibitors from a marine sponge Cribrochalina sp.: revision of the structures of haplosamates A and B. Tetrahedron, 2001, 57(18), 3885-3890.
159. Steffensen, B.; Wallon, U.M.; Overall, C.M. Extracellular matrix binding properties of recombinant fibronectin type II-like modules of human 72-kDa gelatinase/type IV collagenase. High affinity binding to native type I collagen but not native type IV collagen. J. Biol. Chem., 1995, 270(19), 11555-11566.
160. Shipley, J.M.; Doyle, G.A.; Fliszar, C.J.; Ye, Q.Z.; Johnson, L.L.; Shapiro, S.D.; Welgus, H.G.; Senior, R.M. The structural basis for the elastolytic activity of the 92-kDa and 72-kDa gelatinases. Role of the fibronectin type II-like repeats. J. Biol. Chem., 1996, 271(8), 4335-4341.
161. Morgunova, E.; Tuuttila, A.; Bergmann, U.; Isupov, M.; Lindqvist, Y.; Schneider, G.; Tryggvason, K. Structure of human pro-matrix metalloproteinase-2: activation mechanism revealed. Science, 1999, 284(5420), 1667-1670.
162. Berton, A.; Rigot, V.; Huet, E.; Decarme, M.; Eeckhout, Y.; Patthy, L.; Godeau, G.; Hornebeck, W.; Bellon, G.; Emonard, H. Involvement of fibronectin type II repeats in the efficient inhibition of gelatinases A and B by long-chain unsaturated fatty acids. J. Biol. Chem., 2001, 276(23), 20458-20465.
163. Gehrmann, M.; Briknarova, K.; Banyai, L.; Patthy, L.; Llinas, M. The col-1 module of human matrix metalloproteinase-2 (MMP-2): structural/ functional relatedness between gelatin-binding fibronectin type II modules and lysine-binding kringle domains. Biol. Chem., 2002, 383(1), 137-148.
164. Robinet, A.; Emonard, H.; Banyai, L.; Laronze, J.-Y.; Patthy, L.; Hornebeck, W.; Bellon, G. Collagen-binding domains of gelatinase A and thrombospondin-derived peptides impede endocytic clearance of active gelatinase A and promote HT1080 fibrosarcoma cell invasion. Life Sci., 2008, 82(7-8), 376-382.
165. Trexler, M.; Briknarova, K.; Gehrmann, M.; Llinas, M.; Patthy, L. Peptide ligands for the fibronectin type II modules of matrix metalloproteinase 2 (MMP-2). J. Biol. Chem., 2003, 278(14), 12241-12246.
166. Jani, M.; Tordai, H.; Trexler, M.; Banyai, L.; Patthy, L. Hydroxamate-based peptide inhibitors of matrix metalloprotease 2. Biochimie, 2005, 87(3-4), 385-392.
167. Xu, X.; Chen, Z.; Wang, Y.; Bonewald, L.; Steffensen, B. Inhibition of MMP-2 gelatinolysis by targeting exodomain-substrate interactions. Biochem. J., 2007, 406(1), 147-155.
168. Emonard, H.; Marcq, V.; Mirand, C.; Hornebeck, W. Inhibition of gelatinase A by oleic acid. Ann. NY Acad. Sci., 1999, 878, 647-649.
169. Hornebeck, W.; Emonard, H.; Monboisse, J.C.; Bellon, G. Matrix-directed regulation of pericellular proteolysis and tumor progression. Semin. Cancer Biol., 2002, 12(3), 231-241.
170. Brooks, P.C.; Silletti, S.; von Schalscha, T.L.; Friedlander, M.; Cheresh, D.A. Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase fragment with integrin binding activity. Cell, 1998, 92(3), 391-400.
171. Hofmann, U.B.; Westphal, J.R.; Waas, E.T.; Becker, J.C.; Ruiter, D.J.; van Muijen, G.N. Coexpression of integrin alpha(v)beta3 and matrix metalloproteinase-2 (MMP-2) coincides with MMP-2 activation: correlation with melanoma progression. J. Invest. Dermatol., 2000, 115(4), 625-632.
172. 3. J. Am. Chem. Soc., 2001, 123(7), 1280-1288.
173. Silletti, S.; Kessler, T.; Goldberg, J.; Boger, D.L.; Cheresh, D.A. Disruption of matrix metalloproteinase 2 binding to integrin alpha v beta 3 by an organic molecule inhibits angiogenesis and tumor growth in vivo. Proc. Natl Acad. Sci. USA, 2001, 98(1), 119-124.
174. Pasco, S.; Monboisse, J.C.; Kieffer, N. The alpha 3(IV)185-206 peptide from noncollagenous domain 1 of type IV collagen interacts with a novel binding site on the beta 3 subunit of integrin alpha v beta 3 and stimulates focal adhesion kinase and phosphatidylinositol 3-kinase phosphorylation. J. Biol. Chem., 2000, 275(42), 32999-33007.
175. Taniwaki, K.; Fukamachi, H.; Komori, K.; Ohtake, Y.; Nonaka, T.; Sakamoto, T.; Shiomi, T.; Okada, Y.; Itoh, T.; Itohara, S.; Seiki, M.; Yana, I. Stroma-derived matrix metalloproteinase (MMP)-2 promotes membrane type 1-MMP-dependent tumor growth in mice. Cancer Res., 2007, 67(9), 4311-4319.
176. Rittié, L.; Berton, A.; Monboisse, J.C.; Hornebeck, W.; Gillery, P. Decreased contraction of glycated collagen lattices coincides with impaired matrix metalloproteinase production. Biochem. Biophys. Res. Commun., 1999, 264(2), 488-492.
177. Hojo, K.; Maki, H.; Sawada, T.Y.; Maekawa, R.; Yoshioka, T. Augmented growth inhibition of B16-BL6 melanoma by combined treatment with a selective matrix metalloproteinase inhibitor, MMI-166, and cytotoxic agents. Anticancer Res., 2002, 22(6A), 3253-3259.
178. Dabrowska, A.; Giermasz, A.; Marczak, M.; Golab, J.; Jakobisiak, M. Potentiated antitumor effects of interleukin 12 and matrix metalloproteinase inhibitor batimastat against B16F10 melanoma in mice. Anticancer Res., 2000, 20(1A), 391-394.